Brentuximab vedotin in addition to cyclophosphamide, doxorubicin, and prednisolone (CHP) for CD30+ mature T-cell lymphoma
Brentuximab vedotin in addition to cyclophosphamide, doxorubicin, prednisolone (CHP) as intravenous infusion is in development for the treatment of CD30+ mature T-cell lymphoma also known as peripheral T cell lymphoma (PTCL), a subtype of non-Hodgkins lymphoma. PTCL is a group of aggressive and fast growing lymphomas that develop from mature white blood cells called T-cells and natural killer (NK) cells. If the lymphoma cells express a protein called CD30, it is described as CD30+. In most cases, it is not known what causes T-cell lymphoma. Symptoms vary depending the type of T-cell lymphoma and where it develops. Often, the first symptom of lymphoma is a painless swelling of a lymph node or a group of lymph nodes. Clinical outcomes out of the current standard of care for PTCL are insufficient and there are still unmet needs for a new therapy.
Brentuximab vedotin is a monoclonal antibody cancer treatment medicine that lead to cell death selectively in CD30-expressing tumour cells. Brentuximab vedotin in addition to CHP will offer an additional treatment option for patients with CD30+ mature T-cell lymphoma.